Rosenberg J L, Levin B, Wall A J, Kirsner J B
Am J Dig Dis. 1975 Aug;20(8):721-6. doi: 10.1007/BF01070829.
To determine the efficacy of azathioprine in the treatment of Crohn's disease, a 26-week double-blind trial was performed. 20 patients with Crohn's disease, requiring at least 10 mg of prednisone/day over the 3 months prior to entering the study were randomized into placebo (10 patients) and major criterion of success in the trial. There were 7 relapses in the placebo group (5 patients) and 2 relapses in the azathioprine group (2 patients). Complications including fistulae were not affected by the medications. The mean reduction in steriod dosage in the azathioprine group at the end of the trial (-15.5 mg) was greater than in the placebo group (-6.1 mg). These results suggest that azathioprine may permit reduction or discontinuation of steroids without the worsening of symptoms in some patients who appear to require steroids for control of their symptoms. The clinical features of this "AZA-responsive subgroup" remain to be defined.
为确定硫唑嘌呤治疗克罗恩病的疗效，进行了一项为期26周的双盲试验。20例克罗恩病患者在进入研究前的3个月内每天至少需要10毫克泼尼松，这些患者被随机分为安慰剂组（10例患者）和试验成功的主要标准组。安慰剂组有7例复发（5例患者），硫唑嘌呤组有2例复发（2例患者）。包括瘘管在内的并发症不受药物影响。试验结束时硫唑嘌呤组的类固醇剂量平均减少量（-15.5毫克）大于安慰剂组（-6.1毫克）。这些结果表明，硫唑嘌呤可能使某些似乎需要类固醇来控制症状的患者减少或停用类固醇而不使症状恶化。这个“对硫唑嘌呤有反应的亚组”的临床特征仍有待确定。
